Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Biotech-beach save search
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
NVNO | $4.91 6.28% 5.52% 72K
|
Manufacturing
|
| O: -1.22%
H: 0.0%
C: -2.06%
symposium topline medical trial
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
Published: 2024-03-07 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.16 1.13% -20.84% 130
|
Communications
|
| O: 0.79%
H: 0.78%
C: 0.78%
MBIO | $0.34 -0.47% 9.7% 300K
|
Health Technology
|
| O: 8.33%
H: 4.2%
C: -2.8%
FBIO | $1.75 0.57% 150K
|
Health Technology
|
| O: 2.93%
H: 0.0%
C: -9.21%
tumors cell city trial therapy
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Published: 2024-03-06 (Crawled : 14:30) - biospace.com/
NVNO | $4.91 6.28% 5.52% 72K
|
Manufacturing
|
| O: 2.96%
H: 3.48%
C: -9.7%
enous2024 positive topline meeting trial today
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
Published: 2024-02-13 (Crawled : 14:00) - biospace.com/
PBYI | $5.17 3.19% 3.09% 270K
|
Health Technology
|
| O: -0.31%
H: 5.21%
C: -2.05%
lung cancer cell trial
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
Published: 2023-12-11 (Crawled : 14:00) - biospace.com/
PBYI | $5.17 3.19% 3.09% 270K
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: -8.43%
breast cancer trial hormone
Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial
Published: 2023-12-05 (Crawled : 14:30) - biospace.com/
CDTX | News | $0.5139 -24.54% -32.62% 3.7M
|
Health Technology
|
| O: 1.07%
H: 6.26%
C: 1.08%
publication trial therapeutics
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
CDXC | $2.95 -20.05% -24.66% 870K
|
Process Industries
|
| O: 4.51%
H: 2.16%
C: 0.0%
niagen trial milestone
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis
Published: 2023-11-27 (Crawled : 19:00) - biospace.com/
ACAD | News | $16.99 1.01% 1.06% 820K
|
Health Technology
|
| O: -0.45%
H: 0.41%
C: -0.32%
acp-204 disease alzheimer’s treatment pharmaceuticals trial phase 2
enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium
Published: 2023-11-16 (Crawled : 17:00) - biospace.com/
NVNO | $4.91 6.28% 5.52% 72K
|
Manufacturing
|
| O: 0.42%
H: 3.16%
C: -6.32%
device venovalve symposium positive medical trial
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2023-11-02 (Crawled : 14:00) - biospace.com/
RGLS | $2.2 3.29% 3.18% 120K
|
Health Technology
|
| O: 1.63%
H: 8.0%
C: 8.0%
rgls8429 disease kidney treatment trial therapeutics
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
Published: 2023-10-25 (Crawled : 14:00) - biospace.com/
SKYE | $14.81 -8.24% -8.98% 220K
|
Transportation and Warehousing
|
| O: -0.31%
H: 0.0%
C: -23.0%
sbi-100 glaucoma agonist positive bioscience treatment trial results
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Published: 2023-10-19 (Crawled : 12:00) - biospace.com/
HALO M | $38.71 0.18% 0.16% 530K
|
Health Technology
|
| O: 0.95%
H: 0.41%
C: -1.27%
enhanze drug nivolumab renal positive cell topline technology trial results
enVVeno Medical Achieves Full Enrollment for VenoValve U.S. Pivotal Trial
Published: 2023-10-06 (Crawled : 19:00) - biospace.com/
NVNO | $4.91 6.28% 5.52% 72K
|
Manufacturing
|
| O: 2.3%
H: 0.0%
C: -15.66%
venovalve medical trial
City of Hope Opens First U.S. Multicenter Clinical Trial for Robotic Single-Port Mastectomies for Breast Cancer Patients
Published: 2023-10-03 (Crawled : 16:00) - biospace.com/
FNCTF | News | $11.16 1.13% -20.84% 130
|
Communications
| Email alert
Add to watchlist
breast hope cancer city trial
Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials
Published: 2023-07-27 (Crawled : 23:00) - biospace.com/
LGND | $68.53 -5.44% -5.67% 250K
|
Health Technology
|
| O: 0.68%
H: 0.63%
C: -1.09%
pneumococcal vaccine merck trials
Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial
Published: 2023-06-26 (Crawled : 18:00) - biospace.com/
IMMX | $2.13 -2.74% 0.0% 190K
|
|
| O: -2.3%
H: 1.96%
C: -4.71%
nxc-201 fda meeting trial
Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)
Published: 2023-06-05 (Crawled : 12:00) - biospace.com/
GKOS | $98.95 2.54% 0.0% 360K
|
Health Technology
|
| O: 0.08%
H: 1.61%
C: 0.71%
pipeline trial milestone
Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy
Published: 2023-05-31 (Crawled : 21:00) - biospace.com/
ARMP | $2.51 -5.82% 0.0% 5.1K
|
Health Technology
|
| O: 1.49%
H: 6.62%
C: -1.47%
conference presentation pharmaceuticals trial therapy results
Skye Bioscience Begins Dosing Fifth of Six Cohorts in Phase 1 Clinical Trial of Novel CB1R Agonist
Published: 2023-05-17 (Crawled : 14:20) - biospace.com/
SKYE | $14.81 -8.24% -8.98% 220K
|
Transportation and Warehousing
|
| O: 3.45%
H: 3.33%
C: -3.33%
six agonist bioscience trial
Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial
Published: 2023-05-10 (Crawled : 13:20) - biospace.com/
AADI | $1.9 3.26% 3.66% 180K
|
Manufacturing
|
| O: -5.65%
H: 3.12%
C: -11.61%
bioscience update tumor trial financial results
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
PROK | $2.72 33.33% 24.58% 2.6M
|
Your saved searches
Save your searches and get alerts when important news are released.